Cashu
Ionis Pharmaceuticals' Partner Biogen Advances SMA Therapy with Promising Phase 1 Results
2 days ago
Stocks
Health Care
ions
Ionis Pharmaceuticals
IONS
-0.01 (-0.03%)
39.77
USD
At close at Jun 27, 20:41 UTC
Overview
Loading chart...
Key Stats
Market Cap
6.33B
Dividend Yield
0.00%
P/E Ratio
-13.81
EPS
-3.04
Revenue
705.14M
Avg. Volume
2.06M
About
What does IONS do?
Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.